Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.66 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 14/20 | 0.55 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.55 |
| ▸ | CSK | P41240 | 1/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | KIF5B | P33176 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196499 | 0.85 | KDR (0.76) | KDRSRCEPHA2EPHB4CSK | |
| SCHEMBL5217228 | 0.85 | SRC (0.73) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL5214357 | 0.85 | SRC (0.75) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL5215250 | 0.85 | KDR (0.75) | KDRSRCEPHA2EPHB4CSK | |
| SCHEMBL5215259 | 0.85 | KDR (0.75) | KDRSRCEPHA2EPHB4CSK | |
| Hydrochloric Acid SCHEMBL5222294 | 0.84 | KDR (0.67) | KDRSRCRETEGFRFLT1 | |
| Hydrochloric Acid SCHEMBL5215666 | 0.84 | KDR (0.68) | KDRSRCEPHB4CSKRET | |
| SCHEMBL4489459 | 0.83 | SRC (0.56) | SRCERBB2EGFR | |
| SCHEMBL6882002 | 0.82 | SRC (0.67) | KDRSRCEPHA2EPHB4RET | |
| SCHEMBL6881994 | 0.82 | SRC (0.67) | KDRSRCEPHA2EPHB4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040034046-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | US | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034046-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | KDR 1995/4885SRC 2619/4885EPHA2 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.